

General Assembly

Raised Bill No. 285

February Session, 2014

LCO No. 1849



Referred to Committee on COMMITTEE ON CHILDREN

Introduced by: (KID)

AN ACT CONCERNING NEWBORN SCREENING FOR KRABBE DISEASE.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. Section 19a-55 of the 2014 supplement to the general
- 2 statutes is repealed and the following is substituted in lieu thereof
- 3 (Effective July 1, 2014):
- 4 (a) The administrative officer or other person in charge of each
- 5 institution caring for newborn infants shall cause to have administered
- 6 to every such infant in its care an HIV-related test, as defined in section
- 7 19a-581, a test for phenylketonuria and other metabolic diseases,
- 8 hypothyroidism, galactosemia, sickle cell disease, maple syrup urine
- 9 disease, homocystinuria, biotinidase deficiency, congenital adrenal
- 10 hyperplasia and such other tests for inborn errors of metabolism as
- shall be prescribed by the Department of Public Health. The tests shall
- 12 be administered as soon after birth as is medically appropriate. If the
- mother has had an HIV-related test pursuant to section 19a-90 or 19a-
- 14 593, the person responsible for testing under this section may omit an
- 15 HIV-related test. The Commissioner of Public Health shall (1)

LCO No. 1849 **1** of 3

16 administer the newborn screening program, (2) direct persons 17 identified through the screening program to appropriate specialty 18 centers for treatments, consistent with any applicable confidentiality 19 requirements, and (3) set the fees to be charged to institutions to cover 20 all expenses of the comprehensive screening program including 21 testing, tracking and treatment. The fees to be charged pursuant to 22 subdivision (3) of this subsection shall be set at a minimum of fifty-six 23 dollars. The Commissioner of Public Health shall publish a list of all 24 the abnormal conditions for which the department screens newborns 25 under the newborn screening program, which shall include screening 26 for amino acid disorders, organic acid disorders and fatty acid 27 oxidation disorders, including, but not limited to, long-chain 3-28 hydroxyacyl CoA dehydrogenase (L-CHAD) and medium-chain acyl-29 CoA dehydrogenase (MCAD).

(b) In addition to the testing requirements prescribed in subsection (a) of this section, the administrative officer or other person in charge of each institution caring for newborn infants shall cause to have administered to every such infant in its care (1) a screening test for cystic fibrosis, (2) a screening test for severe combined immunodeficiency disease, [and (3) on and after January 1, 2013,] (3) a screening test for critical congenital heart disease, and (4) on and after January 1, 2015, a screening test for globoid cell leukodystrophy. Such screening tests shall be administered as soon after birth as is medically appropriate.

30

31

32

33

34

35

36

37

38

39

40 (c) On and after the occurrence of the following: (1) The 41 development and validation of a reliable methodology for screening 42 newborns for adrenoleukodystrophy using dried blood spots and 43 quality assurance testing methodology for such test or the approval of 44 a test for adrenoleukodystrophy using dried blood spots by the federal 45 Food and Drug Administration; and (2) the availability of any 46 necessary reagents for such test, the administrative officer or other 47 person in charge of each institution caring for newborn infants shall 48 cause to have administered to every such infant in its care a test for

LCO No. 1849 **2** of 3

49 adrenoleukodystrophy.

50

51

52

53

54

(d) The provisions of this section shall not apply to any infant whose parents object to the test or treatment as being in conflict with their religious tenets and practice. The commissioner shall adopt regulations, in accordance with the provisions of chapter 54, to implement the provisions of this section.

This act shall take effect as follows and shall amend the following sections:		
sections.		
Section 1	July 1, 2014	19a-55

Statement of Purpose:

To require newborn screening for globoid cell leukodystrophy.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]

LCO No. 1849 3 of 3